

CURRICULUM VITAE

A. PERSONAL INFORMATION

Julie Brumer Dumond, PharmD, MS
Associate Professor, Division Director of Graduate Studies
Division of Pharmacotherapy and Experimental Therapeutics
Eshelman School of Pharmacy
University of North Carolina at Chapel Hill
1093 Genetic Medicine, Campus Box 7361
120 Mason Farm Rd.
Chapel Hill, NC 27599-7361
Phone: (919) 966-5017
Fax: (919) 966-1020
E-mail: jdumond@unc.edu

B. EDUCATION

- 2012 Master of Science, Pharmaceutical Sciences (Pharmacometrics), State University of New York, University at Buffalo, Buffalo, NY
- 2004 Doctor of Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, MI
- 2000 Bachelor of Science, Lyman Briggs School Field of Concentration in Physical Sciences, Michigan State University, East Lansing, MI

C. PROFESSIONAL EXPERIENCE

- 2021- present Associate Professor with Tenure, University of North Carolina at Chapel Hill, UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics
- 2013-2021 Assistant Professor, University of North Carolina at Chapel Hill, UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics
- 2009-2013 Research Assistant Professor, University of North Carolina at Chapel Hill, UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics
Director, Pharmacometrics Core
- 2009-2010 Clinic Pharmacist, UNC Healthcare, Infectious Diseases Clinic
- 2007-2009 Assistant Professor, East Tennessee State University, Gatton College of Pharmacy, Department of Pharmacy Practice, Johnson City, TN
Pharmacist, ETSU HIV/AIDS Center of Excellence
Preceptor, Inpatient Infectious Diseases, Johnson City Medical Center

- 2005-2007 HIV Pharmacology Fellow (ACCP-accredited), University of North Carolina at Chapel Hill, UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics
Clinic Pharmacist, UNC Healthcare, Infectious Diseases Clinic
- 2004-2005 Pharmacy Practice Residency (ASHP-accredited), Borgess Medical Center, Kalamazoo, MI
Clinical Instructor, Ferris State University, Department of Pharmacy Practice, Big Rapids, MI

D. HONORS & AWARDS

- 2014 Cold Spring Harbor Laboratory Fourth Annual Workshop on Leadership in Bioscience
Scholarship Recipient and Attendee
- 2014 HIV and Aging: From Mitochondria to the Metropolis, Junior Investigator Research
Mentoring Workshop Attendee
- 2009 2008-2009 Outstanding Teacher, ETSU Gatton College of Pharmacy Class of 2011
- 2005 Young Investigator Award, 13th Conference on Retroviruses and Opportunistic Infections
- 2003-2004 University of Michigan College of Pharmacy Research Award
APhA-ASP Senior Recognition Award
Albert B. Prescott Memorial Scholarship
Dean's Scholarship for Highest Academic Distinction
Plough Scholarship, Charles R. Walgreen Scholarship
- 2003 Rho Chi Honor Society, Alpha Chapter
- 2002-2003 University of Michigan College of Pharmacy Alumni Award
Dean's Scholarship for Highest Academic Distinction
Plough Scholarship
Charles R. Walgreen Scholarship
- 2001-2002 University of Michigan College of Pharmacy Rho Chi Award
Dean's Scholarship for High Academic Distinction
- 2000 Phi Beta Kappa, Epsilon of Michigan Chapter

E. BIBLIOGRAPHY

Books & Chapters

1. Cottrell ML, Nicol MR and **Dumond JB**. Prevention: Preexposure Prophylaxis and Postexposure Prophylaxis. In: Tseng A and Stewart A, eds. HIV Pharmacotherapy, 2nd ed. Bethesda, MD: American Society of Health-Systems Pharmacists, 2025 *in press*.
2. Adams JA, **Dumond JB** and Kashuba ADM. Human Immunodeficiency Virus Infection. In: Koda-Kimble MA, Young LY, Kradjan WA et al., eds. Applied Therapeutics: The Clinical Use of Drugs. 9th ed. Lippincott Williams and Wilkins, 2008. Revised: 10th ed. Lippincott Williams and Wilkins, 2011.

3. Corbett A, Yeh R, **Dumond J**, and Kashuba ADM. Human Immunodeficiency Virus Infection. In: Chisholm-Burns MA, Wells BG, Schwinghammer TL, et al, eds. Pharmacotherapy Principles and Practice. 1st ed. New York City: MacGraw-Hill, 2008. Revised: 2nd ed. New York City: MacGraw-Hill, 2010. Revised: 3rd ed. New York City: MacGraw-Hill, 2012.

Refereed Publications

1. Khoei A, Edmonds A, Chang Y, Wolinsky S, Ho K, Brown T, Margolick J, Kempf M-C, Alcaide M, Lahiri CD, Ofotokun I, Sheth A, Gange S, French A, Tamraz B, Aouizerat BE, Tien PC, Merenstein D, DeHovitz J, Anastos A, **Dumond JB**. A Novel Concentration-Based Time-Imputation Algorithm for Large Cohort Studies Missing Time-After-Dose Data for Stored Samples.. CPT:PSP 2025; *in review*.
2. Mann SC, Lykins D, Coyle RP, Witt MD, Kim E-Y, Macatangay B, Brown TT, Dionne-Odom J, Alcaide M, Lahiri CD, Ramirez C, **Dumond JB**, D'Souza GA, Cohen MH, Wilson T, Kassaye S, Tien P, Adedimeji AA, Ellison L, Brooks KM, Bushman LR, Anderson PL, MaWhinney S, Castillo-Mancilla JR. In the Mismatch: Viral Suppression Despite Low Tenofovir Diphosphate in Dried Blood Spots (DBS) in the Multicenter AIDS Cohort Study/Women's Interagency HIV Study Combined Cohort (MWCCS). CID 2025; *in review*.
3. Huang Y, Zhang L, Lemos M, Astronomo R, Narpala S, Prabhakaran M, Garcia NM, Lu Y, Mize G, Glantz H; Colegrove H, Mann P, Paez C, Andersen-Nissen E, Hutter J, **Dumond J**, McDermott A, Mascola J, Koup R, Bekker L-G, McElrath MJ. Pharmacokinetics Analysis of Serum and Rectal Tissue Concentrations of a Pair of anti-HIV monoclonal antibodies, VRC01 and VRC01LS, in Adults Without HIV. JCP 2025; *in revision*.
4. Yu MA, Gerig L, Mehta CC, Musonge-Effoe J, Alvarez JA, Ofotokun I, Ali MK, Ziegler TR, Yang Q, Spence AB, Albrecht S, Alcaide ML, **Dumond JB**, Abraham AG, French AL, Augenbraun M, Anastos K, Price J, Tien PC, Lahiri CD. Increased Risk of Hepatic Steatosis Following Integrase Inhibitor Initiation in Women with HIV. CID 2025; *in press*.
5. Neverette NC, **Dumond JB**, McMahon DK, Devanathan AS. Lenacapavir: Playing the Long Game in the New Era of Antiretrovirals. Clin Pharmacol Ther. 2025 Feb;117(2):353-367. doi: 10.1002/cpt.3447. Epub 2024 Sep 25. Erratum in: Clin Pharmacol Ther. 2025 May;117(5):1470. doi: 10.1002/cpt.3647. PMID: 39323028; PMCID: PMC11739746.
6. Lahiri CD, Mehta CC, Yang Q, Maramba T, Musonge-Effoe J, Yang CA, **Dumond JB**, Alcaide ML, Lake JE, Rubin LH, French AL, Cocohoba J, Kassaye SG, Sharma A, Palella FJ, Mellors J, Konkle-Parker D, Topper E, Augenbraun M, Ali MK, Sheth AN, Ziegler TR, Ofotokun I, Alvarez JA. Short and Long-term Body Weight Change Following the Switch to or the Addition of Integrase Inhibitors in Persons With HIV Differs by Sex. Clin Infect Dis. 2025 Mar 17;80(3):575-584. doi: 10.1093/cid/ciae474. PMID: 39324701; PMCID: PMC11912967.
7. **Dumond JB**. Intracellular dried blood spot metabolite concentrations for assessing antiretroviral adherence and HIV progression. Pharmacotherapy. 2025 Mar;45(3):152-154. doi: 10.1002/phar.70001. Epub 2025 Feb 13. PMID: 39945481.

8. Devanathan AS, Poliseno AJ, White NR, Schauer AP, Sykes C, Weideman AMK, Kilpatrick KW, Hudgens MG, Gay CL, Rosen EP, **Dumond JB**, Kashuba ADM, Cottrell ML. A Cross-Biomeasure Study to Optimize Antiretroviral Adherence Estimation. *J Acquir Immune Defic Syndr*. 2025 Mar 1;98(3):291-299. doi: 10.1097/QAI.0000000000003570. PMID: 39813294..
9. Yu MA, Gerig L, Mehta CC, Musonge-Effoe J, Alvarez JA, Ofotokun I, Sheth AN, Ali MK, Ziegler TR, Yang Q, Spence AB, Alcaide ML, **Dumond JB**, Abraham AG, French AL, Augenbraun M, Anastos K, Price JC, Tien PC, Lahiri CD. Non-invasive markers of hepatic steatosis and fibrosis following INSTI initiation in women with HIV. *Clin Infect Dis*. 2025 Feb 3:ciaf049. doi: 10.1093/cid/ciaf049. Epub ahead of print. PMID: 39899358.
10. Thompson EJ, Gonzalez D, **Dumond J**, Hornik CP, Kilborn A, Laughon MM, Jackson WM. Population Pharmacokinetics of Caffeine in Infants with Hypoxic-Ischemic Encephalopathy: A Phase I, Dose-Escalating Trial. *J Clin Pharmacol*. 2025 Feb 12. doi: 10.1002/jcph.70004. Epub ahead of print. PMID: 39936359.
11. Walsh SR, Gay CL, Karuna ST, Hyrien O, Skalland T, Mayer KH, Sobieszczyk ME, Baden LR, Goepfert PA, Del Rio C, Pantaleo G, Andrew P, Karg C, He Z, Lu H, Paez CA, Baumblatt JAG, Polakowski LL, Chege W, Anderson MA, Janto S, Han X, Huang Y, **Dumond J**, Ackerman ME, McDermott AB, Flach B, Piwowar-Manning E, Seaton K, Tomaras GD, Montefiori DC, Gama L, Mascola JR; HVTN 127/HPTN 087 Study Team. Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial. *PLoS Med*. 2024 Jun 24;21(6):e1004329. doi: 10.1371/journal.pmed.1004329. PMID: 38913710; PMCID: PMC11251612.
12. Cluck DB, Chastain DB, Murray M, Durham SH, Chahine EB, Derrick C, **Dumond JB**, Hester EK, Jeter SB, Johnson MD, Kilcrease C, Kufel WD, Kwong J, Ladak AF, Patel N, Pérez SE, Poe JB, Bolch C, Thomas I, Asiago-Reddy E, Short WR. Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and/or have multidrug-resistant HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy: An executive summary. *Pharmacotherapy*. 2024 May;44(5):354-359. doi: 10.1002/phar.2913. PMID: 38853605.
13. Cluck DB, Chastain DB, Murray M, Durham SH, Chahine EB, Derrick C, **Dumond JB**, Hester EK, Jeter SB, Johnson MD, Kilcrease C, Kufel WD, Kwong J, Ladak AF, Patel N, Pérez SE, Poe JB, Bolch C, Thomas I, Asiago-Reddy E, Short WR. Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and/or have multidrug-resistant HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy. *Pharmacotherapy*. 2024 May;44(5):360-382. doi: 10.1002/phar.2914. PMID: 38853601.
14. Kinsale TS, Cottrell ML, Li L, Brand R, Gatto G, Luecke E, Norton C, Krovi A, **Dumond JB**, Rao G, Yeshwante S, Van Horne B, Van Der Straten A, Kashuba ADM, Johnson LM. Pharmacokinetic Modeling to Guide Preclinical Development of an Islatravir-Eluting Reservoir-Style Biodegradable Implant for Long-Acting HIV PrEP. *Pharmaceutics*. 2024 Jan 30;16(2):201. doi: 10.3390/pharmaceutics16020201. PMID: 38399255; PMCID: PMC10893066.

15. Edrosolan KA, Shlipak MG, Scherzer R, Estrella MM, Gustafson D, Karim R, Fisher M, Cohen M, Kassaye S, **Dumond J**, Abraham A, McCulloch CE, Ascher SB. Mediation analysis of chronic kidney disease risk factors using kidney biomarkers in women living with HIV. *AIDS*. 2024 May 1;38(6):813-824. doi: 10.1097/QAD.0000000000003839. Epub 2024 Jan 12. PMID: 38224361; PMCID: PMC11025668.
16. Fashe MM, Le TV, Gower MN, Mulrenin IR, Dorman KF, Smith S, Fallon JK, **Dumond JB**, Boggess KA, Lee CR. Impact of Pregnancy on the Pharmacokinetics and Metabolism of Nicotinamide in Humans. *Clin Pharmacol Ther*. 2024 Mar;115(3):556-564. doi: 10.1002/cpt.3146. Epub 2024 Jan 11. PMID: 38093631; PMCID: PMC11250906.
17. Leung E, Cottrell ML, Sykes C, White N, Kashuba ADM, **Dumond JB**. A multicompartment population PK model to predict tenofovir and emtricitabine mucosal tissue concentrations for HIV prevention. *CPT Pharmacometrics Syst Pharmacol*. 2023 Dec;12(12):1922-1930. doi: 10.1002/psp4.13042. Epub 2023 Oct 9. PMID: 37814498; PMCID: PMC10725258.
18. Byrnes JR, Lee TK, Sharaby S, Campbell RA, Dobson D, Holle LA, Luo M, Kangro K, Homeister J, Aleman MM, Luyendyk JP, Kerlin BA, **Dumond JB**, Wolberg AS. Reciprocal stabilization of coagulation factor XIII-A and -B subunits determines plasma FXIII concentration. *Blood*. 2023 Oct 26;blood.2023022042. doi: 10.1182/blood.2023022042. Epub ahead of print. PMID: 37883802.
19. Garimella PS, Scherzer R, Kestenbaum BR, Hoofnagle AN, Jotwani V, Gustafson D, Karim R, Sharma A, Cohen M, **Dumond J**, Abraham A, Estrella M, Shlipak MG, Ix JH. Tubular Secretory Solute Clearance and HIV Infection. *J Acquir Immune Defic Syndr*. 2023 Aug 1;93(4):319-326. doi: 10.1097/QAI.0000000000003200. PMID: 36988544; PMCID: PMC10313730.
20. Salerno SN, Capparelli EV, McIlleron H, Gerhart JG, **Dumond JB**, Kashuba ADM, Denti P, Gonzalez D. Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients. *Pharmacotherapy*. 2023 Jul;43(7):638-649. doi: 10.1002/phar.2703. Epub 2022 Jun 8. PMID: 35607886; PMCID: PMC9684348.
21. Devanathan AS, **Dumond JB**, Anderson DJC, Moody K, Polisen AJ, Schauer AP, Sykes C, Gay CL, Rosen EP, Kashuba ADM, Cottrell ML. A Novel Algorithm to Improve PrEP Adherence Monitoring Using Dried Blood Spots. *Clin Pharmacol Ther*. 2023 Jan 9. doi: 10.1002/cpt.2845. Epub ahead of print. PMID: 36622798.
22. Ding H, George S, Leng XI, Ihnat M, Ma JX, Jiang G, Margolis D, **Dumond J**, Zhang Y. Silk fibers assisted long-term 3D culture of human primary urinary stem cells via inhibition of senescence-associated genes: Potential use in the assessment of chronic mitochondrial toxicity. *Mater Today Adv*. 2022 Aug;15:100261. doi: 10.1016/j.mtadv.2022.100261. Epub 2022 Jun 14. PMID: 36212078; PMCID: PMC9542430.
23. Kayes T, Crane H, Symonds A, **Dumond J**, Cottrell M, Di Girolamo J, Manandhar S, Lim TH, Gane E, Kashuba A, Levy MT. Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection. *Aliment Pharmacol Ther*. 2022 Aug;56(3):510-518. doi: 10.1111/apt.17040. Epub 2022 May 22. Erratum in: *Aliment Pharmacol Ther*. 2023 Jan 24; PMID: 35599363.

24. Salerno SN, Capparelli EV, McIlleron H, Gerhart JG, **Dumond JB**, Kashuba ADM, Denti P, Gonzalez D. Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients. *Pharmacotherapy*. 2022 May 24;10.1002/phar.2703. doi: 10.1002/phar.2703. Epub ahead of print. PMID: 35607886; PMCID: PMC9684348.
25. Gbolahan OB, O'Neil BH, McRee AJ, Sanoff HK, Fallon JK, Smith PC, Ivanova A, Moore DT, **Dumond J**, Asher GN. A phase I evaluation of the effect of curcumin on dose-limiting toxicity and pharmacokinetics of irinotecan in participants with solid tumors. *Clin Transl Sci*. 2022 May;15(5):1304-1315. doi: 10.1111/cts.13250. Epub 2022 Feb 26. PMID: 35157783; PMCID: PMC9099132.
26. Chen J, Titanji K, Sheth AN, Gandhi R, McMahan D, Ofotokun I, Weitzmann MN, De Paris K, Dumond JB. The effect of age on CD4+ T-cell recovery in HIV-suppressed adult participants: a sub-study from AIDS Clinical Trial Group (ACTG) A5321 and the Bone Loss and Immune Reconstitution (BLIR) study. *Immun Ageing*. 2022 Jan 3;19(1):4. doi: 10.1186/s12979-021-00260-x. PMID: 34980186; PMCID: PMC8722153.
27. Morbitzer KA, McLaughlin JE, Ozawa S, Beechinor RJ, **Dumond JB**, Pomykal C, Bush AA, Zhang Q, Carpenter DM, Lee CR. Implementation and initial evaluation of a research and scholarship training pathway in a PharmD curriculum. *Am J Pharm Educ* 2021 Jan 1; 85(1): <https://www.ajpe.org/content/85/1/8079>.
28. Soudeyns H and **Dumond J**. Invited Comment: Unexpectedly low levels of transplacental transfer of second-generation integrase strand transfer inhibitors bictegravir and cabotegravir. *AIDS*. 2020 Nov 15;34(14):2137-2139. doi: 10.1097/QAD.0000000000002634.
29. **Dumond JB**, Bay CP, Nelson JAE, Davalos A, Edmonds A, De Paris K, Sykes C, Anastos K, Sharma R, Kassaye S, Tamraz B, French AL, Gange S, Ofotokun I, Fischl MA, Vance DE, Adimora AA. Intracellular Tenofovir and Emtricitabine Concentrations in Younger and Older Women with HIV Receiving Tenofovir Disoproxil Fumarate/Emtricitabine. *Antimicrob Agents Chemother*. 2020 Aug 20;64(9):e00177-20. doi: 10.1128/AAC.00177-20.
30. Saag MS and **Dumond JB**. Invited Comment: Déjà vu all over again. *AIDS*. 2019 Nov 1;33(13):2097-2098. doi: 10.1097/QAD.0000000000002314.
31. Hornik CP, Gonzalez D, **Dumond J**, Wu H, Graham EM, Hill KD, Cohen-Wolkowicz M. Population Pharmacokinetic/Pharmacodynamic Modeling of Methylprednisolone in Neonates Undergoing Cardiopulmonary Bypass. *CPT Pharmacometrics Syst Pharmacol*. 2019 Dec;8(12):913-922. doi: 10.1002/psp4.12470. Epub 2019 Oct 23.
32. Greene SA, Chen J, Prince HMA, Sykes C, Schauer AP, Blake K, Nelson JAE, Gay CL, Cohen MS, **Dumond JB**. Population Modeling Highlights Drug Disposition Differences Between Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in the Blood and Semen. *Clin Pharmacol Ther*. *Clin Pharmacol Ther*. 2019 Oct;106(4):821-830. doi: 10.1002/cpt.1464. Epub 2019 May 31.
33. Cottrell ML and **Dumond JB**. Invited Comment: Pharmacology Points to Potential PrEP Pitfalls. *Lancet HIV*; 2018 Nov 29. pii: S2352-3018(18)30318-7. doi: 10.1016/S2352-3018(18)30318-7. [Epub ahead of print].

34. **Dumond JB**, Greene SA, Prince HMA, Chen J, Maas BL, Sykes C, Schauer AP, Blake K, Julie AE, Nelson JAE, Gay CL, Kashuba ADM, Cohen MS. Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract. *Antiviral Ther* 2018 Oct 30. doi: 10.3851/IMP3277. [Epub ahead of print].
35. Garrett KL, Chen J, Maas BM, Cottrell ML, Prince HA, Sykes C, Schauer AP, White N, **Dumond JB**. A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs. *J Pharmacol Exp Ther*. 2018 Nov;367(2):245-251. doi: 10.1124/jpet.118.251009. Epub 2018 Aug 27.
36. Chen J, Akhtari FS, Wagner MJ, Suzuki O, Wiltshire T, Motsinger-Reif AA, **Dumond JB**. Pharmacogenetic Analysis of the Model-based Pharmacokinetics of Five Anti-HIV Drugs: How Does This Influence the Effect of Aging? *Clin Transl Sci*. 2017 Dec 3. doi: 10.1111/cts.12525. [Epub ahead of print].
37. Collins JW, Hull JH, **Dumond JB**. Comparison of Tenofovir Plasma and Tissue Exposure Using a Population Pharmacokinetic Model and Bootstrap: A Simulation Study from Observed Data. *J PK PD*; 2017 Dec;44(6):631-640. doi: 10.1007/s10928-017-9554-9. Epub 2017 Nov 8.
38. Geller EJ, **Dumond JB**, Bowling JM, Khandelwal CM, Wu JM, Busby-Whitehead J, Kaufer DI. Female Pelvic Med Reconstr Surg. 2017 Jan 18. [Epub ahead of print].
39. Maas BM, Francis O, Lee C, Cottrell ML, Prince HMA, Mollan KR, Sykes C, Trezza C, Torrice C, White N, Malone S, Hudgens MG, Sharpless NE, **Dumond JB**. Concentrations of Pro-Inflammatory Cytokines Are Not Associated with Senescence Marker p16INK4a or Predictive of Intracellular Emtricitabine/Tenofovir Metabolite and Endogenous Nucleotide Exposures in Adults with HIV Infection. *PLoS One*, *PLoS One*. 2016 Dec 30;11(12):e0168709.
40. **Dumond JB**, Chen J, Cottrell ML, Trezza C, Prince HMA, Malone S, Sykes C, Torrice C, White N, Wang R, Wagner M, Patterson KB, Sharpless NE, Forrest A. Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV+ Subjects with Aging Biomarkers. *CPT Pharmacometrics Syst Pharmacol*. 2016 Dec 29.
41. **Dumond JB**, Collins JW, Cottrell ML, Trezza C, Prince HMA, Malone S, Sykes C, Torrice C, White N, Wang R, Wagner M, Patterson KB, Sharpless NE, Forrest A. A Senescence Marker, p16INK4a, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIV+ Subjects. *CPT Pharmacometrics Syst Pharmacol*. 2016 Dec 26.
42. Chen J, Malone S, Prince HMA, Patterson KB, **Dumond JB**. Model-Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women Supports Standard Dosing in the Third Trimester. *CPT Pharmacometrics Syst. Pharmacol*. 2016; 5:147–157.
43. **Dumond JB**, Francis O, Cottrell M, Trezza C, Prince HMA, Mollan K, Sykes C, Torrice C, White N, Malone S, Wang R, Van Dam C, Patterson KB, Hudgens MG, Sharpless NE, Forrest A. Tenofovir/Emtricitabine Metabolites and Endogenous Nucleotide Exposures are Associated with p16INK4a Expression in Subjects on Combination Therapy. *Antivir Ther*. 2016 Jan 5. [Epub ahead of print].

44. **Dumond JB**, Yang KH, Kendrick R, Reddy YS, Kashuba AD, Troiani L, Bridges AS, Fiscus SA, Forrest A, Cohen MS. Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells. *Antimicrob Agents Chemother.* 2015 Oct;59(10):6395-401. Epub 2015 Aug 3.
45. **Dumond JB**, Rigdon J, Mollan K, Tierney C, Kashuba AD, Aweeka F, Collier AC. Significant Decreases in both Total and Unbound Lopinavir and Amprenavir Exposures during Co-administration: ACTG Protocol A5143/A5147s Results. *J Acquir Immune Defic Syndr.* 2015 Dec 15;70(5):510-4. Epub 2015 Jul 30.
46. Greener BN, Patterson KB, Prince HM, Sykes CS, Adams JL, **Dumond JB**, Shaheen NJ, Madanick RD, Dellon ES, Cohen MS, Kashuba AD. Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing. *J Acquir Immune Defic Syndr.* 2013;64:39-44.
47. Adams JL, Patterson KB, Prince HM, Sykes C, Greener BN, **Dumond JB**, Kashuba AD. Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women. *Antivir Ther.; Antivir Ther.* 2014;18(8):1005-13. Epub 2013 Jul 31.
48. **Dumond JB**, Adams JL, Prince HMA, Kendrick RL, Wang R, Jennings SH, Malone S, White N, Sykes C, Corbett AH, Patterson KB, Forrest A, Kashuba ADM. Pharmacokinetics of Two Common Antiretroviral Regimens in Older HIV-Infected Patients: A Pilot Study. *HIV Medicine*; 2013 Feb 24. [Epub ahead of print].
49. Patterson KB, **Dumond JB**, Prince HA, Jenkins AJ, Scarsi KK, Wang R, Malone S, Hudgens MG, Kashuba AD. Protein Binding of Lopinavir and Ritonavir During Four Phases of Pregnancy: Implications for Treatment Guidelines. *J Acquir Immune Defic Syndr.* 2012 Dec 6. [Epub ahead of print].
50. Wohl DA, **Dumond JB**, Blevins S, Pittard D, Ragan D, Wang R, Massengale K, Walsh K, Floris-Moore M, Eron JJ Jr, Richardson A, Hudgens M, Kashuba AD. Raltegravir Pharmacokinetics in Treatment-Naïve Patients is not influenced by Race: Results from the Raltegravir Early Therapy in African Americans Living with HIV (REAL) Study. *Antimicrob Agents Chemother.* 2013 Feb; 57:784-8. Epub 2012 Nov 26.
51. **Dumond JB**, Nicol MR, Kendrick RN, Garonzik SM, Patterson KB, Cohen MS, Forrest A, Kashuba ADM. Pharmacokinetic Modelling of Efavirenz, Atazanavir, Lamivudine, and Tenofovir in the Female Genital Tract of HIV-Infected Pre-Menopausal Women. *Clin Pharmacokinet.* 2012; 51:809-22.
52. Geller EJ, Crane AK, Wells EC, Robinson BL, Jannelli ML, Khandelwal CM, Connolly A, Parnell BA, Matthews CA, **Dumond JB**, Busby-Whitehead J. Effect of anticholinergic use for the treatment of overactive bladder on cognitive function in postmenopausal women. *Clin Drug Investig.* 2012; 32:697-705.
53. Kashuba AD, Patterson KB, **Dumond JB**, Cohen MS. Pre-exposure prophylaxis for HIV prevention: how to predict success. *Lancet* 2012; 379(9835):2409-11; [Epub ahead of print, Dec. 6, 2011].

54. Kwaru A, Tashima K, **Dumond J**, Poethke P, Kurpewski J, Kashuba A, Court MH, Greenblatt DH. Modest but Variable Effect of Rifampin on Steady-State Plasma Pharmacokinetics of Efavirenz in Healthy African American and Caucasian Volunteers. *Antimicrob Agents Chemo* 2011;55(7):3527-33. Epub 2011 Apr 25.
55. Brown KC, Patterson KB, Malone SA, Shaheen NJ, Prince HMA, **Dumond JB**, Spacek M, Heidt PE, Cohen MS, and Kashuba ADM. Single and Multiple Dose Pharmacokinetics of Maraviroc in Saliva, Semen, and Rectal Tissue of Healthy HIV-Negative Men. *J Infect Dis*; 2011;203:1484-90.
56. **Dumond JB**, Vourvahis M, Rezk NL, Patterson KB, Tien H, White N, Jennings S, Choi SO, Li J, Wagner MJ, La I, Drulak M, Sabo JP, Castles MA, MacGregor TR, Kashuba ADM. A Phenotype-Genotype Approach to Predicting CYP450 and P-glycoprotein Drug Interactions with the Mixed Inhibitor/Inducer Tipranavir/ritonavir. *Clinical Pharmacol Ther* 2010; 87:735-42.
57. **Dumond JB**, Patterson KB, Pecha AL, Werner RE, Andrews E, Damle B, Tressler R, Worsley J, Kashuba ADM. Maraviroc Concentrates in Cervicovaginal Fluid and Vaginal Tissue of HIV Negative Women. *J Acquir Immune Defic Syndr*. 2009; 51:546-553.
58. Yeh RF, Rezk NL, Kashuba ADM, **Dumond JB**, Tappouni HL, Tien H, Chen Y, Vourvahis M, Horton AL, Fiscus SA, Patterson KB. Genital Tract, Cord Blood, and Amniotic Fluid Exposures of 6 Antiretroviral Drugs During Pregnancy and Postpartum. *Antimicrob Agents Chemo* 2009; 53:2367-2374.
59. **Dumond JB**, Reddy YS, Troiani L, Rodriguez JF, Bridges AS, Fiscus SA, Yuen GJ, Cohen MS, Kashuba AD. Differential Extracellular and Intracellular Concentrations of Zidovudine and Lamivudine In Semen and Plasma of HIV-1 Infected Men. *J Acquir Immune Defic Syndr*. 2008; 48:156-162.
60. **Dumond JB**, Yeh RF, Patterson KB, Corbett AH, Jung BH, Rezk NL, Bridges AS, Stewart PW, Cohen MS, Kashuba ADM. Antiretroviral Drug Exposure in the Female Genital Tract: Implications for Oral Pre- and Post-Exposure Prophylaxis. *AIDS* 2007; 21: 1899-1907.
61. Shedden K, **Brumer J**, Chang YT, and Rosania GR. Chemoinformatic Analysis of a Supertargeted Combinatorial Library of Styryl Molecules. *J Chem Info Comput Sci* 2003; 43: 2068-2080

Refereed Presentations

1. Oliveira D, Cottrell M, **Dumond J**, King J, Le T, Schauer A, Benhabbour SR. A Modeling Approach to Expedite the Development of a New Long-Acting Controlled-Release Multipurpose Formulation Containing Medroxyprogesterone Acetate. ASCPT 2025, National Harbor, MD, May 28-30, 2025.
2. **Dumond JB**, Sykes C, Schauer A, Kashuba A, Cottrell M*. Optimizing On-Demand Tenofovir Disoproxil Fumarate/Emtricitabine Dosing in Women for HIV Prevention. CROI 2025, San Francisco, CA, March 10-13, 2025. (oral; *presenter)
3. Lahiri CD, Mehta CC, Yang Q, **Dumond JB**, Alcaide ML, Palella F, Lake JE, Rubin LH, French AL, Kassaye S, Augenbraun M, Sharma A, Ofotokun I, Sheth AN, Alvarez JA. Change in Cardiometabolic Risk Markers Following Switch to Integrase Inhibitors Differs by Sex. CROI 2025, San Francisco, CA, March 10-13, 2025.

4. Huang Y, Zhang L, Lemos M, Astronomo R, Narpala S, Prabhakaran M, Garcia NM, Lu Y, Mize G, Glantz H; Colegrove H, Mann P, Paez C, Andersen-Nissen E, Hutter J, **Dumond J**, McDermott A, Mascola J, Koup R, Bekker L-G, McElrath MJ. Pharmacokinetics Analysis of Serum and Rectal Tissue Concentrations of a Pair of anti-HIV monoclonal antibodies, VRC01 and VRC01LS, in Adults Without HIV. ACoP 2024, Phoenix, AZ, November 10-13, 2024.
5. Khoei A, Edmonds A, Chang Y, Wolinsky S, Ho K, Brown T, Margolick J, Kempf M-C, Alcaide M, Lahiri CD, Ofotokun I, Sheth A, Gange S, French A, Tamraz B, Aouizerat BE, Tien PC, Merenstein D, DeHovitz J, Anastos A, **Dumond JB**. A Novel Concentration-Based Time-Imputation Algorithm for Large Cohort Studies Missing Time-After-Dose Data for Stored Samples. ACoP 2024, Phoenix, AZ, November 10-13, 2024.
6. Mann SC, Lykins D, Coyle RP, Witt MD, Kim E-Y, Macatangay B, Brown TT, Dionne-Odom J, Alcaide M, Lahiri CD, Ramirez C, **Dumond JB**, D'Souza GA, Cohen MH, Wilson T, Kassaye S, Tien P, Adedimeji AA, Ellison L, Brooks KM, Bushman LR, Anderson PL, MaWhinney S, Castillo-Mancilla JR. In the Mismatch: Viral Suppression Despite Low Tenofovir Diphosphate in Dried Blood Spots (DBS) in the Multicenter AIDS Cohort Study/Women's Interagency HIV Study Combined Cohort (MWCCS). AIDS 2024, Munich, Germany, July 23-26, 2024.
7. Lahiri CD, Mehta CC, Yang Q, Musonge-Effoe J, **Dumond J**, Alcaide M, Wolinsky S, Lake JE, Mellors J, Rubin LH, Topper E, Konkle-Parker D, French A, Cocohoba J, Kassaye S, Augenbraun M, Sharma A, Sheth AN, Ofotokun I, Alvarez JA. Short and Long-term Body Weight Gain Following Switch to Integrase Inhibitors Differs by Sex. CROI 2024, Denver, CO. March 3-6, 2024.
8. Lahiri CD, **Dumond J**, Mehta CC, Yang Q, Sheth AN, Ofotokun I, Sykes C, Hartauer M, Khoei A, Alcaide M, Lake JE, Rubin LH, Konkle-Parker D, Adimora AA, Topper EF, French AL, Cocohoba J, Kassaye S, Augenbraun M, Sharma A, Tien PC. "Association Between Integrase Inhibitor Plasma Concentrations and Body Weight Gain in Women Living with HIV", ID Week, Boston, MA, October 13, 2023 (Oral).
9. Devanathan AS, **Dumond JB**, Anderson DJC, Moody K, Poliseno AJ, Schauer AP, Sykes C, Gay CL, Rosen EP, Kashuba ADM, Cottrell ML. A New Algorithm to Improve Adherence Classification Using Dried Blood Spots for Daily and On-Demand PrEP. International Workshop on Clinical Pharmacology on HIV, Hepatitis & Other Antiviral Drugs 2022. September 19-22, 2022. Oral Presentation #5.
10. Kayes T, Crane H, Symonds A, Di Girolamo J, Manandhar S, **Dumond J**, Kashuba A, Lim TH, Gane E, Levy M. Breast Milk Pharmacokinetics of Tenofovir Alafenamide (Vemlidy®) in the Setting of Chronic Hepatitis B Infection. The Liver Meeting 2021. November 2021.
11. **Dumond JB**, Cottrell ML, Symonds AE, Sykes C, White N, Kashuba AD. Predicted Success of PrEP Users' Preferred Nondaily Tenofovir/Emtricitabine Regimens. Science Spotlight, CROI 2021. February 2021.
12. Morbitzer KA, McLaughlin JE, Olsen AA, Zhang Q, **Dumond J**, Carpenter D, Ozawa S, Smith PC, Bush A, Pomykal C, Lee CR. Implementation and initial evaluation of an innovative approach to research and scholarship training in pharmacy education. American College of Clinical Pharmacy Annual Meeting 2019. October 2019.

13. La MK, Morbitzer K, Cook AM, Hatton-Kolpek J, Jordon JD, Nelson NR, **Dumond J**, Rhoney DH. Levetiracetam Pharmacokinetics and Dose Optimization for Seizure Prophylaxis in Moderate-to-Severe Traumatic Brain Injury. Neurocritical Care Society Annual Meeting 2018. September 2018.
14. **Dumond JB**, Bay C, Nelson JAE, Sykes C, Anastos K, Sharma R, Kassaye S, Villacres M, Greenblatt R, French A, Gange SJ, Ofofokun I, Fischl M, Vance D, Adimora A. Higher NRTI Metabolite:Endogenous Nucleotide Ratios in Older HIV+ Women on TDF/FTC. Conference on Retroviruses and Opportunistic Infections 2018. March 2018. Abstract 464.
15. Garrett K, Maas B, Cottrell M, Prince H, Sykes C, Schauer A, White N, Kashuba A, **Dumond J**. Tenofovir Alafenamide (TAF) for HIV Prevention in IV Drug Users. ACoP8. October 2017. Abstract T-081.
16. Greene SG, Garrett KL, Prince HMA, Chen J, Maas B, SykesD, SchauerA, Gay CL, Kashuba ADM, Cohen MS, **Dumond JB**. Population Pharmacokinetics of Tenofovir and Tenofovir Diphosphate in the Blood, Semen, and Mononuclear Cells of Healthy and HIV-Positive Men Receiving Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide. ACoP8. October 2017. Abstract W-037.
17. Chen J, Gandhi R, McMahon D, Bosch R, Eron J, **Dumond J**. Population Modeling of Longitudinal CD4+ T-cell Recovery Up to 15 Years: The Effect of Aging. ACoP8. October 2017. Abstract T-074.
18. **Dumond JB**, Greene SA, Prince HMA, Chen J, Maas BM, Sykes C, Schauer AP, Gay CL, Kashuba ADM, Cohen MS. Extra/Intra-cellular Nucleoside/tide Semen Pharmacology: Implications for Eradication. Conference on Retroviruses and Opportunistic Infections 2017. February 2017. Discussed Poster 406.
19. Chen J, **Dumond JB**. Exploratory Analysis of Age on Longitudinal CD4+ T-Cell Reconstitution in HIV-Infected Patients Using a Semi-mechanistic Model. ACoP7. October 2016. Abstract W-38.
20. Collins JW, Hull JH, **Dumond JB**. Comparative Estimation of Human Tissue Exposure Following Partial Destructive Sampling Scheme Using Bootstrapped Noncompartmental Methods vs Non-linear Mixed Effects Models (NLME). ACoP7. October 2016. Abstract T-43.
21. Cottrell ML, Chen J, MS; Maas BM, Prince H, Sykes C, White N, Kashuba ADM, **Dumond JB**. A PK/PD Model to Predict Effective HIV PrEP Dosing Strategies for IV Drug Users. HIVR4P 2016. October 2016. Abstract P21.12LB.
22. Chen J, Prince HMA, Trezza C, Cottrell ML, Malone S, Sykes C, White N, Wang R, Wagner M, Patterson KB, Forrest A, **Dumond JB**. Pharmacokinetic and pharmacogenetic analysis of Unbound Atazanavir (ATV), Ritonavir (RTV) and Efavirenz (EFV) in HIV-infected Patients. 17th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, June 2016. Abstract P_68.
23. **Dumond JB**, Francis O, Trezza CR, Messer J, Lee C, Cottrell M, Prince HMA, Mollan K, Sykes C, Torrice C, White N, Malone S, Wang R, Patterson KB, Forrest A, Hudgens MG, Sharpless NE, Kashuba ADM. Association of a Senescence Biomarker with Intracellular Nucleotide Metabolite and Endogenous Nucleotide Exposures in HIV+ Subjects Receiving Tenofovir/Emtricitabine. 16th International Workshop on the Clinical Pharmacology of HIV Infection, May 2015. Abstract P_30.

24. Collins JW, Trezza CR, Prince HMA, Cottrell ML, Sykes C, White N, Malone S, Wang R, Torrice C, Sharpless NE, Patterson KB, Forrest A, Kashuba ADM, **Dumond JB**. Aging Effects as Covariates in the Population Pharmacokinetics (PK) of Emtricitabine (FTC) and Intracellular Emtricitabine Triphosphate (FTC-TP) in HIV+ Subjects. 16th International Workshop on the Clinical Pharmacology of HIV Infection, May 2015. Abstract P_43.
25. **Dumond JB**, Trezza CR, Francis O, Prince HMA, Mollan K, Cottrell M, Sykes C, Torrice C, White N, Malone S, Wang R, Patterson KB, Forrest A, Hudgens MG, Sharpless NE, Kashuba ADM. Tenofovir (TFV), Emtricitabine (FTC), Intracellular Metabolite, and Endogenous Nucleotide (EN) Concentrations as a Function of Aging in HIV+ Subjects. AIDS 2014, July 2014. Abstract THPDB0105 (Discussed Poster).
26. **Dumond JB**, Trezza CR, Prince HMA, Cottrell C, Sykes C, White N, Malone S, Wang R, Patterson KB, Forrest A, Kashuba ADM. Population Pharmacokinetic (PK) Modeling of Tenofovir (TFV), Emtricitabine (FTC), and Their Intracellular Metabolites in HIV+ Subjects. 15th International Workshop on the Clinical Pharmacology of HIV Infection, May 2014. Abstract P_34.
27. Greener BN, Adams JL, Patterson KB, Prince HMA, Sykes C, Wai M, **Dumond JB**, Shaheen N, Cohen MS, Kashuba ADM. Single and Multiple Dose Dolutegravir (DTG) Pharmacokinetics (PK) in the Genital Tract (GT) and Colorectum of HIV Negative Men and Women. 20th Conference on Retroviruses and Opportunistic Infections, March 2013. Abstract J-138.
28. **Dumond JB**, Adams JA, Prince HMA, Kendrick RN, White N, Sykes C, Corbett AH, Patterson KB, Forrest A, Kashuba AD. Tenofovir Diphosphate (TFV-DP) and Emtricitabine Triphosphate (FTC-TP) Pharmacokinetics (PK) in Older HIV+ Patients. 13th International Workshop on the Clinical Pharmacology of HIV Infection. April 2012. Abstract P_25.
29. **Dumond JB**, Nicol MR, Kendrick RN, Garonzik SM, Patterson KB, Cohen MS, Forrest A, Kashuba ADM. Pharmacokinetic Modelling of Efavirenz, Atazanavir, Lamivudine, and Tenofovir in the Female Genital Tract of HIV-Infected Pre-Menopausal Women. 13th International Workshop on the Clinical Pharmacology of HIV Infection. April 2012. Abstract O_14. (Platform Presentation).
30. **Dumond JB**, Adams JL, Prince HMA, Kendrick R, Wang R, Jennings S, Malone S, Corbett AH, Patterson KB, Forrest A, Kashuba ADM. Pharmacokinetics of Two Common Antiretroviral Regimens in Older HIV-Infected Patients: A Pilot Study. 2nd International Workshop on HIV and Aging. October 2011. Abstract O_12. (Platform Presentation).
31. Patterson KB, **Dumond JB**, Prince HA, Jenkins A, Scarsci K, Wang R, Malone S, Hudgens MB, Kashuba ADM. Pharmacokinetics (PK) of the Lopinavir/Ritonavir (LPV/r) Tablet in HIV-infected Pregnant Women: A Longitudinal Investigation of Protein Bound and Unbound Drug Exposure With Empiric Dosage Adjustment. 18th Conference on Retroviruses and Opportunistic Infections, February 2011. Abstract 645.
32. Patterson KB, **Dumond JB**, Prince HA, Kraft E, Eron JJ, Kashuba ADM. Pharmacokinetics (PK) of Tenofovir (TFV) Disoproxil Fumarate (TDF) in Blood Plasma (BP) and Cervicovaginal Fluid (CVF) of HIV-infected Post-menopausal Women (PMW) Compared with Pre-menopausal Women (Pre-MW). 18th Conference on Retroviruses and Opportunistic Infections, February 2011. Abstract 32 (Platform Presentation, KB Patterson).

33. Kendrick RN, **Dumond JB**, Forrest A, Cohen MS, Kashuba ADM. Pharmacokinetic Model for Zidovudine and Lamivudine and their Intracellular Metabolites in Blood and Semen. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2010. Abstract A1-2106.
34. Kwara A, Tashima K, **Dumond J**, Poethke P, Kurpewski J, Kashuba A, Court MH, Greenblatt DH. Effect of Rifampin on Efavirenz Pharmacokinetics. Poster 066. American College of Clinical Pharmacology 39th Annual Meeting, September 2010.
35. Wohl D, **Dumond J**, Blevins S, Pittard D, Ragan D, Wang R, Carpenter K, Floris-Moore M, Eron J, Kashuba A. Raltegravir Pharmacokinetics in Treatment Nave Patients is Not Influenced by Race: PK Results from the Early Therapy in African Americans Living with HIV Study. Abstract 16042. XVIII International AIDS Conference. July 2010.
36. Brown KC, Patterson KB, Malone SA, Shaheen NJ, Prince HMA, **Dumond JB**, Spacek M, Heidt PE, Cohen MS, and Kashuba ADM. Antiretrovirals (ARVs) for Prevention: Maraviroc (MVC) Exposure in the Semen (SE) and Rectal Tissue (RT) of Healthy Male Volunteers after Single and Multiple Dosing. 17th Conference on Retroviruses and Opportunistic Infections, February 2010. (Platform Presentation, KC Brown).
37. **Dumond JB**, Patterson KB, Pecha A, et al. Maraviroc Pharmacokinetics in Blood Plasma, Genital Tract Fluid and Tissue in Healthy Female Volunteers. Abstract 135LB. 15th Conference on Retroviruses and Opportunistic Infections, February 2008. (Platform Presentation, KB Patterson).
38. Vourvahis M, **Dumond J**, Patterson KB et al. Effects of Tipranavir/ritonavir on the Activity of Cytochrome P450 Enzymes 1A2, 2C9, and 2D6 in Healthy Volunteers. 8th International Workshop on Clinical Pharmacology of HIV Therapy, April 2007. (Platform Presentation, M Vourvahis).
39. Vourvahis M, **Dumond J**, Patterson KB et al. Effects of Tipranavir/ritonavir on the Activity of Hepatic and Intestinal Cytochrome P450 3A4/5 and P-glycoprotein: Implications for Drug Interactions. Abstract L-150. 14th Conference on Retroviruses and Opportunistic Infections (CROI), February 2007.
40. Yeh RF, Patterson KB, **Dumond JB** et al. Genital Tract, Cord Blood, and Amniotic Fluid Exposures of 6 Antiretroviral Drugs During Pregnancy and Postpartum. Abstract 888 (A-0378). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2006.
41. **Dumond J**, Yeh R, Patterson K et al. First Dose and Steady-state Genital Tract Pharmacokinetics of Ten Antiretroviral Drugs in HIV-infected Women: Implications for Pre- and Post- Exposure Prophylaxis. UNC Women's Health Research Day, April 2006. (Platform Presentation).
42. **Dumond J**, Yeh R, Patterson K et al. First Dose and Steady-state Genital Tract Pharmacokinetics of Ten Antiretroviral Drugs in HIV-infected Women: Implications for Pre- and Post- Exposure Prophylaxis. Abstract T-119. 13th CROI. February 2006. (Platform Presentation).
43. Shedden K, **Brumer J**, and Rosania G. A Library Approach to the Discovery of Subcellular Localization Signals Encoded in the Chemical Structure of Small Molecules. Poster M1091. American Association of Pharmaceutical Sciences Meeting, 2003.

Products of Creative Activity

1. **Dumond JB.** Pharmacometrics Skills Competition MIDD Gran Prix. April 27, 2018. Blog post on Certara's Model-Informed Drug Development website. Available electronically [here](#).

Non-Refereed Publications and Presentations

1. Dumond JB. Sex Differences in Dolutegravir Exposure and Weight-Related Conditions. 2023 Inter-CFAR Working Group on HIV in Women Meeting. San Francisco, CA. December 6-7, 2023.
2. Nicol MR and **Dumond JB.** How to Prepare a Competitive Grant Application: Ten Tips for Success. Society of Infectious Diseases Pharmacists Research Committee Webinar, July 2021.
3. **Dumond JB,** Roland M, and Kashuba ADM. Understanding Primary and Secondary HIV Prophylaxis – Part I: Non-occupational Post-Exposure Prophylaxis and Antiretroviral Pharmacokinetics in the Male and Female Genital Tract. The PRN Notebook 2006; 11(2):10-16.
4. **Dumond JB.** Eating Disorders: Focus on Pharmacotherapy. Michigan Pharmacist 2004;42(2): 48-56.
5. **Dumond JB,** Bickel RJ, and Klepser ME. Evaluation of Vancomycin Tolerance in Blood Isolates of Methicillin-Resistant Staphylococcus aureus (MRSA): Prevalence, Susceptibility Patterns and Clinical Outcomes. Poster RP-304. 2004 ASHP Midyear Clinical Meeting.

F. TEACHING ACTIVITIES

Term	Course (Number, Title, Type)	Approximate Enrollment	Role
Spring 2025	DPET 857: Population PK/PD Graduate (elective), 2 credits Phoenix NLME for PopPK, (4hrs)	8	Instructor
	PHCY 726: <i>Research and Scholarship in Pharmacy 3</i> , Professional (elective), 3 credit hours Networking and Scientific Meetings (1.5 hrs)	15	Instructor
Fall 2024	DPET 853: Pharmacokinetic Concepts and Applications Graduate (required), 1.75 credits	22	Module Director
	DPET 854: Pharmacodynamic Concepts and Applications Graduate (required), 1.25 credits	10	Module Director
Spring 2024	DPET 857: Population PK/PD Graduate (elective), 2 credits Phoenix NLME for PopPK, (4hrs)	8	Instructor

	PHCY 726: <i>Research and Scholarship in Pharmacy 3</i> , Professional (elective), 3 credit hours Preparing a Poster Presentation (1.5 hrs) Networking and Scientific Meetings (1.5 hrs)	24	Instructor
Fall 2023	DPET 853: Pharmacokinetic Concepts and Applications Graduate (required), 1.75 credits	19	Module Director
	DPET 854: Pharmacodynamic Concepts and Applications Graduate (required), 1.25 credits	9	Module Director
Spring 2023	PHCY 725: <i>Research and Scholarship in Pharmacy 2</i> , Professional (elective), 3 credit hours (2 x 8-week blocks of 1.5 credits each)	28	DPET Co-Director
	PHCY 726: <i>Research and Scholarship in Pharmacy 3</i> , Professional (elective), 3 credit hours	35	Course Co-Director
Fall 2022	PHCY 624: <i>Research and Scholarship in Pharmacy 1</i> , Professional (elective), 3 credits hours (2 x 8-week blocks of 1.5 credits each)	28	DPET Co-Director
	DPET 853: Principles of Pharmacokinetics, Graduate (required), 1.75 credits	12	Module Director
	PHCY 725: <i>Research and Scholarship in Pharmacy 2</i> , Professional (elective), 3 credit hours (2 x 8-week blocks of 1.5 credits each)	35	DPET Co-Director
Spring 2022	PHCY 726: <i>Research and Scholarship in Pharmacy 3</i> , Professional (elective), 3 credit hours	40	Course Co-Director
	PHCY 624: <i>Research and Scholarship in Pharmacy 1</i> , Professional (elective), 3 credits hours (2 x 8-week blocks of 1.5 credits each)	35	DPET Co-Director
Fall 2021	DPET 853: Principles of Pharmacokinetics, Graduate (required), 1.75 credits	30	Module Director

	PHCY 725: <i>Research and Scholarship in Pharmacy 2</i> , Professional (elective), 3 credit hours (2 x 8-week blocks of 1.5 credits each)	40	DPET Co-Director
Spring 2021	PHCY 726: <i>Research and Scholarship in Pharmacy 3</i> , Professional (elective), 3 credit hours	25	Course Co-Director
	PHCY 624: <i>Research and Scholarship in Pharmacy 1</i> , Professional (elective), 3 credits hours (2 x 8-week blocks of 1.5 credits each)	40	DPET Co-Director
Fall 2020	DPET 853: Principles of Pharmacokinetics, Graduate (required), 1.75 credits	25	Module Director
	PHCY 725: <i>Research and Scholarship in Pharmacy 2</i> , Professional (elective), 3 credit hours (2 x 8-week blocks of 1.5 credits each)	40	DPET Co-Director
Fall 2019	DPET 853: Principles of Pharmacokinetics, Graduate (required), 1.75 credits	25	Module Director
	PHCY 725: <i>Research and Scholarship in Pharmacy 2</i> , Professional (elective), 3 credit hours (2 x 8-week blocks of 1.5 credits each)	25	DPET Co-Director
Spring 2019	PHCY 624: <i>Research and Scholarship in Pharmacy 1</i> , Professional (elective), 3 credits hours (2 x 8-week blocks of 1.5 credits each)	15	DPET Co-Director
	PHCY 726: <i>Research and Scholarship in Pharmacy 3</i> , Professional (elective), 3 credit hours	25	DPET Co-Director
	DPET 853: <i>Principles of Pharmacokinetics</i> , Graduate (required), 1.75 credits	25	Module Director
Fall 2018	PHCY 725: <i>Research and Scholarship in Pharmacy 2</i> , Professional (elective), 3 credit hours (2 x 8-week blocks of 1.5 credits each)	26	DPET Co-Director

Spring 2018	PHCY 624: <i>Research and Scholarship in Pharmacy 1</i> , Professional (elective), 3 credits hours (2 x 8-week blocks of 1.5 credits each)	30	DPET Co-Director
	PHCY 726: <i>Research and Scholarship in Pharmacy 3</i> , Professional (elective), 3 credit hours	30	DPET Co-Director
Fall 2017	DPET 853: <i>Principles of Pharmacokinetics</i> , Graduate (required), 1.75 credit hours	20	Module Director
	PHCY 725: <i>Research and Scholarship in Pharmacy 2</i> , Professional (elective), 3 credit hours (2 x 8-week blocks of 1.5 credits each)	26	DPET Co-Director

Advising
Graduate Students

- 2024—present Nathan Engle. Dissertation Title: to be determined
Role: Co-Major Advisor
- 2024—present Jiali (Wendy) Wen, PharmD. Dissertation Title:
Role: Dissertation Advisory Committee
- 2022—present Mattie Hartauer. Dissertation Title: to be determined
Role: Chair, Dissertation Advisory Committee
- 2022—present Elizabeth Thompson, MD. Dissertation Title: to be determined
Role: Chair, Dissertation Advisory Committee
- 2022—2024 Sean McCann. Dissertation Title: Using Real-World Data to Evaluate Sources of Pharmacokinetic Variability in Critically Ill Children
Role: Dissertation Advisory Committee
- 2021– present Adrian Khoei, PharmD. Dissertation Title: Unraveling the Cardiometabolic Conundrum: Dolutegravir and Tenofovir Alafenamide Exposure in ART-experienced People with HIV
Role: Major Advisor
- 2021—present Patty Maglalang, PharmD. Dissertation Title: Characterizing Sources of Pharmacokinetic/Pharmacodynamic Variability of Antiseizure Medication Disposition in Pediatric Patients
Role: Chair, Dissertation Advisory Committee
- 2020 – 2022 Estefany Garcia, PharmD. Dissertation Title: Optimizing Antimicrobial Combination Dosing for Resistant ESKAPE Pathogens
Role: Chair, Dissertation Advisory Committee

- 2019 – 2023 Talisa Kinsale. Tentative Dissertation Title: Novel In Vitro/In Vivo Methods for Development of Small-Molecule Combination HIV Eradication Strategies.
Role: Dissertation Advisory Committee 2019-6/2023; Chair, 7/2023-12/2023
- 2017 - 2020 Sara Salerno, PharmD. Graduated December 2020. Dissertation Title: PBPK Modeling of Complex Drug-Drug Interactions in Children.
Role: Dissertation Advisory Committee
- 2016-2019 Christoph Hornik, MD, MPH. Graduated May 2019. Dissertation Title: Optimizing Pediatric Clinical Trial Sample Size Estimations
Role: Dissertation Advisory Committee
- 2014-2018 Jingxian Chen, M.S. Graduated May 2018. Dissertation Title: Nonlinear Mixed Effects Modeling of HIV-infected Special Populations
Role: Dissertation Advisory Committee, Major Advisor
- 2012-2016 Kevin Watt, MD. Graduated August 2016. Dissertation Title: Physiologically Based Pharmacokinetics in Critically Ill Children.
Role: Dissertation Advisory Committee
- 2014-2015 John Mellnik, PhD. Graduated May 2015, Applied Math Curriculum. Dissertation Title: Microrheology and Heterogeneity in Biological Fluids: Approaches, Models and Applications
Role: Dissertation Advisory Committee
- 2009-2011 Tae Eun Kim, PhD. Graduated December 2011. Dissertation Title: The Impact of Pharmacodynamic Parameters on Prediction of Clinical Outcome in HIV-1 Infected Patients and HCV Patients with HIV Co-Infection
Role: Dissertation Advisory Committee

Graduate Student Rotations

- Fall 2021 Mattie Hartauer, 1st year DPET graduate student.
Project: Predicting HIV Integrase Inhibitor Concentrations from Sparse Plasma Samples in the Women's Interagency HIV Study Cohort

Post-Doctoral Fellows

- 2023-2025 Daniel Oliviera, PharmD, UNC/Certara PK/PD Fellow
- 2022-2024 Taek Lee, PharmD, UNC/Certara PK/PD Fellow
- 2021-2023 Erick Leung, PharmD, UNC/Certara PK/PD Fellow
- 2020-2022 Allison Symonds, PharmD, UNC/Certara PK/PD Fellow
- 2019-2021 Brian Jermain, PharmD, UNC/Nuventra Pharmacometrics Fellow
- 2018-2020 Lana Tran, PharmD, UNC/PPD Drug Development Fellow
- 2017-2019 Sherif Sharaby, PharmD, UNC/Quintiles PK/PD Fellow

2016-2018 Stephen Greene, PharmD, UNC/Nuventra Pharmacometrics Fellow

2015-2017 Brian Maas, PharmD, UNC/Quintiles Pharmacometrics Fellow

2014-2016 Jon Collins, PharmD, UNC/GlaxoSmithKline PK/PD Fellow

2013-2014 Shalini Yapa, PhD, UNC/GlaxoSmithKline PK/PD Fellow

2013-2014 Christine Trezza Anderson, PharmD, UNC/GlaxoSmithKline Drug Development Fellow

2012-2015 Mackenzie Cottrell, PharmD, HIV Clinical Pharmacology Fellow and UNC/Duke T32 Clinical Pharmacology Fellow

Pharmacy Practice Residents (Teaching Certificate Program)

2014-2015 Kalyann Rhode, PharmD

2013-2014 Roseann Gammal, PharmD

Doctor of Pharmacy Research and Scholarship in Pharmacy Students

2025—present Kieran O'Reilly (Class of 2027)

2024—present Joshua Airgood (Class of 2026)
Kendall Poythress (Class of 2026)

2023—2025 Christina Sabu (Class of 2025)
Margaux Meilhac (Class of 2025)
Emilia Pieta (Class of 2025)

2022—2024 Andrea Dobbs (Class of 2024)

2021-2023 Grace Hoffman (Class of 2023)

Fall 2021 Lucy Goodacre, University College London Pharmacy Student
3rd year elective research experience

2018-2020 Marissa Ross, PharmD

2017-2020 Emily Wings, PharmD

Doctor of Pharmacy Honors Students

2013-2016 Cynthia Lee

2014-2015 Jordan Messer

2009-2011 Brianna Franklin

G. GRANTS

Pending

National Institutes of Health (NHLBI 1U01HL146194; Study MPI: Floris-Moore, Drummond; 04/01/2026 - 03/31/2031)

UNC MACS/WIHS Combined Cohort Study Clinical Research Site

Role: Investigator, Working Group Chair; 10% effort

Total direct grant amount: \$ 17,985,783

National Institutes of Health (NHLBI; Study PI: P. Tien; 04/01/2026 - 03/31/2031)

MWCCS Leadership and Coordination Center, University of California San Francisco

Role: Investigator, Working Group Chair; 2% effort

Total direct grant amount: \$ 687,950 (UNC Subaward; UNC MPI: Floris-Moore, Drummond)

National Institutes of Health (NIAID; Study PI: L. Johnson, RTI; 9/1/2025-3/31/2030)

Delivery of Antiretrovirals via Implantable System for Young children with Translational Work for new Options (DAISY-TWO)

Role: Co-Investigator; 10% effort

Total direct grant amount: \$1,015,725 (UNC Subaward; UNC PI: M. Cottrell)

National Institutes of Health (NCI; Study PI: J. Lifson; 9/1/2025-3/31/2030)

Mechanisms of SHIV Prevention in Nonhuman Primates: Pharmacokinetics Core

Role: Core Investigator; 10% effort

Total direct grant amount: \$1,269,102 (UNC Subaward; UNC PI: A. Kashuba)

F32 Application for Jordan Winfield, PharmD, Postdoctoral Fellow, University of Pittsburg School of Pharmacy; to be submitted 5/7/2025; 9/1/2025-8/31/2027)

Role: Co-Sponsor (no salary support)

Current

National Institutes of Health (NICHD 5-R01-HD096435-01-05; Study PI: D. Gonzalez; 9/1/2018-7/31/2025)

Physiologically-Based Pharmacokinetic Modeling to Guide Drug Dosing in Children with Obesity

Role: Subaward PI

Total direct grant amount: \$214,861; 2% effort (no-cost extension)

National Institutes of Health (NHLBI DP1HL174180; Study PI: Devanathan AS; 5/2024 – 4/2029)

Multiomics and Antiretroviral Drug Exposure for assessing Metabolic Effects (MADE-FOR-ME)

Role: Co-Investigator

Total direct grant amount: \$40,616 (UNC Subaward); 5% effort

National Institutes of Health (NIAID U24AI179403; Study PI: Cottrell ML; 1/12/2024-12/31/2028)
HIV Pharmacology Data Repository

Role: Co-Investigator

Total direct grant amount: \$2,712,094; 15% effort

DHHS FDA National Center for Toxicological Research (Study PI: Wang Y, UNC Consortium PI: Zamboni W; 1/1/2024-12/31/2025)

Evaluating the Effect of Obesity on the Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies in Pediatric Patients

Role: Co-Investigator

Total direct grant amount: \$172,038 (UNC Subaward); 7.5% effort

National Institutes of Health (NIAID R01AI153007; 4/9/21-8/31/2026)

Quantifying Sex-and-Age-Related Differences in Antiretroviral Exposure and Adverse Effects in the MACS/WIHS Combined Cohort Study

Role: Principal Investigator

Total direct grant amount: \$3,453,949; 20% effort

National Institutes of Health (NHLBI 1U01HL146194; Study MPI: Floris-Moore, Drummond; 04/01/19 - 03/31/26)

UNC MACS/WIHS Combined Cohort Study Clinical Research Site

Role: Investigator

Total direct grant amount: \$1,951,086; 10% effort

Completed

National Institutes of Health (NHLBI 2R01-HL126974; Study PI: Alisa Wolberg; 7/1/20-6/30/25)

Fibrinogen and Factor XIII in Venous Thromboembolism

Role: Other Key Participant

Total direct grant amount: \$1,832,290, 10% effort (years 1&2)

National Institutes of Health (NIA R21AG063660; 8/15/19-4/30/22)

Interaction of Nucleoside Reverse Transcriptase Inhibitor Pharmacology and Aging in the Multicenter AIDS Cohort Study

Role: Principal Investigator

Total direct grant amount: \$277,141; 30% effort

National Institutes of Health (NIAID R21-AI145646; Study PI: Cottrell M; 4/9/2019-3/31/21)

Feminizing Sex Hormones Impact on PrEP Pharmacology in Transgender Women

Role: Pharmacometrics Collaborator

Total direct grant amount: \$264,496; fee-for-service

National Institutes of Health (NIA R21AG058490; 9/30/18-5/31/21)

Effects of Aging and Inflammation on Intracellular Nucleoside Reverse Transcriptase Inhibitor Pharmacology in the WIHS Cohort

Role: Principal Investigator

Total direct grant amount: \$240,509; 15% effort

National Institutes of Health (NIDDK 5R01 DK108424-02; Study PI: Cohen MS; 09/01/15-07/31/20)

The Compartmental Biology of HIV in the Male Genital Tract

Role: Co-Investigator

Total direct grant amount: \$2,000,000; 10% effort (Years 1-4)

National Institutes of Health (NIAID A18-0692-003; Study PI: Aouizerat, BE; 08/31/17-12/31/18)

Epigenomics of ethnic and racial disparities in ARV exposure and treatment outcomes

Role: Co-Investigator

Total direct supplement amount: \$7,077; 2% effort

National Institutes of Health (NIAID U01 AI103390; Study PI: Adimora, A; 01/01/13-12/31/18)
Women's Interagency HIV Study (WIHS)
Role: Co-Investigator, Working Group Chair
Total direct grant amount: \$1,793,708; 5% effort

UNC Center for AIDS Research Developmental Award; Study PI: Dumond (09/01/16-8/31/17)
Role: Principal Investigator
Total direct grant amount: \$30,000 (research support only)

National Institutes of Health (NIAID K23 AI093156; Study PI: Dumond; 3/1/11-2/28/17)
Optimizing Antiretroviral Use in Aging: Pharmacokinetics, Response, and Toxicity
Role: Principal Investigator
Total direct grant amount: \$506,635; 75% effort

Society of Infectious Diseases Pharmacists Research Award (9/1/09-8/31/10)
Extracellular and Intracellular Atripla (Tenofovir/Emtricitabine/Efavirenz) Pharmacokinetics in the Aging HIV Infected Population
Role: Principal Investigator
Total direct grant amount: \$10,000 (research support only)

NC TraCS Institute \$50K Pilot Grant Award (04/15/2010 – 07/14/2011)
Extracellular and Intracellular Atripla (Tenofovir/Emtricitabine/Efavirenz) Pharmacokinetics in the Aging HIV Infected Population
Role: Principal Investigator
Total direct grant amount: \$50,000 (research support only; \$25,000 matching funds from UNC Eshelman School of Pharmacy and UNC Center for AIDS Research)

Merck Investigator-Initiated Study (Study PI: Stuart G; 2012-2013)
Pharmacokinetics, pharmacodynamics, and genital tract viral shedding in HIV+ women using combined oral contraceptives and raltegravir
Role: Co-Investigator
Total direct grant amount: \$387,748.91; 10% effort

GlaxoSmithKline (Study PI: Patterson KB; 2011-2013)
GSK 572 Pharmacokinetics in Blood Plasma, Cervicovaginal Fluid, Vaginal Tissue, and Cervical Tissue in HIV-negative Volunteers
GSK 572 Pharmacokinetics in Blood Plasma, Semen, Rectal Fluid, and Rectal Tissue in HIV-negative Volunteers
Role: Co-Investigator
Total direct grant amount: \$668,000, fee-for-service

Family Health International/USAID (Sub-contract PI: Kashuba; 2011-2012)
Truvada for Prevention of HIV in Women (FEM-PrEP) Pharmacology Sub-Contract
Role: Investigator
Total direct grant amount: \$ 417,020, fee-for-service

National Institutes of Health (NIAID U01-AI095031-01; Study PI: Kashuba; 7/1/11-6/30/16)
Preventing HIV Infection in Women: Targeting Antiretrovirals to Mucosal Tissues
Role: Investigator
Total direct grant amount: \$2,470,515; fee-for-service

National Institutes of Health (NIAID U19-AI096113-01; Study PI: Margolis D; 7/1/11-6/30/16)
Martin Delaney Collaboratory to Cure HIV-1
Role: Technical Staff, Pharmacology Core
Total direct grant amount: \$6,380,150; fee-for-service

NC TraCS Institute \$10K Award (Study PI: Kashuba; 10/09-8/11)
Development and Validation of a Multiplex Mass Spectrometry Assay for Antimicrobials in Premature Infants
Role: Collaborator (Pharmacometrics Core)
Total direct grant amount: \$10,000 (research support only)

Abbott Virology (Study PIs: Kashuba, Patterson; 1/07-12/08)
The Effect of Pregnancy on the Pharmacokinetics of Kaletra® (lopinavir/ritonavir) Tablets: A Longitudinal Investigation in the Second and Third Trimesters Including Empiric Dosage Adjustment
Role: Co-Investigator
Total direct grant amount: \$187,000

Pfizer, Inc., (Study PI: Kashuba; 11/06-12/07)
A Phase I, Open Label, Study in Healthy Female Subjects to Investigate the Extent of Maraviroc Exposure in Blood, Cervicovaginal Fluid, and Vaginal Tissue Following Single and Multiple Dosing of Maraviroc
Role: Co-Investigator
Total direct grant amount: \$349,000

American College of Clinical Pharmacy and Ortho-McNeil Infectious Diseases Fellowship (7/06-7/07)
Mentor: ADM Kashuba
Role: Supported Fellow
Total direct grant amount: \$42,000

Boehringer-Ingelheim Pharmaceuticals, Inc, (Study PI: Kashuba; 1/06-6/07)
Evaluating the Effects of Tipranavir (with Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-Glycoprotein Activity Using a Biomarker Cocktail in Healthy Volunteers
Role: Co-Investigator
Total direct grant amount: \$1,668,280

H. PROFESSIONAL SERVICE

Service to the Discipline

Editorial Board

Clinical Pharmacology and Therapeutics
Pharmacotherapy

Journal Peer Reviewer

AIDS
Pharmacotherapy
Annals of Pharmacotherapy
JAIDS
Journal of Antimicrobial Chemotherapy
Clinical Pharmacokinetics
Antiviral Therapy
Lancet HIV

Scientific Planning Committees

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2024. September 18-20, 2024. Liverpool, UK. Sponsor: Academic Medical Education.

Scientific Consultant

Clinical Pharmacologist, Male Contraceptive Initiative
Regulatory Guidance for Industry Working Group Member

Clinical Pharmacologist, HIV Prevention Trials Network (HPTN)

Protocol Development Teams:

HIV Vaccine Trials Network (HVTN) 127/HPTN 087: A multicenter, randomized, partially blinded phase 1 clinical trial to evaluate the safety and serum concentrations of a human monoclonal antibody, VRC-HIVMAB075-00-AB (VRC07 523LS), administered in multiple doses and routes to healthy, HIV-uninfected adults.

HVTN 129/HPTN 088: A phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and functional activity of a trispecific antibody, SAR441236, in healthy, HIV-1-uninfected adult participants.

HVTN 130/HPTN 089: A phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of combinations of monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered via intravenous infusion in healthy, HIV-uninfected adult participants.

HVTN 136/HPTN 092: A phase 1 dose-escalation clinical trial to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of the monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS via intravenous or subcutaneous infusions in healthy, HIV-uninfected adult participants.

Grant Peer Reviewer

- 2025 NIH Center for Scientific Review
ZRG1 DCAI-D (03), Member Conflict: Topics in HIV research
- 2024 NIDA Contract Review
RFP: 75N95024R00078: The Pharmacokinetic Analysis Resource Center
- NIH Center for Scientific Review
ZRG1 IIDA-K02 Member Conflict: Topics on HIV Virology, Immunopathogenesis, Drug and Vaccine Development
- 2023 NIH Center for Scientific Review
HIV Comorbidities and Clinical Studies Study Section (HCCS)
Infectious Diseases and Immunology B Integrated Review Group
Ad-Hoc Member, July 2023
- NIH Center for Scientific Review
Member, Special Emphasis Panel ZRG1 IIDB-Q (02)
Member Conflict: Topics in HIV and AIDS, April 2023

- 2022 NIH Center for Scientific Review
Member, Special Emphasis Panel ZAI1-KSW-A-J1
RFA-AI-22-025: Enhancing HIV Reservoir Susceptibility to Elimination (R01 Clinical Trial Not Allowed), November 2022
- 2021 NIH Center for Scientific Review,
AIDS Research Review Charter Committee for the review of an application for a single K99 NIH Pathway to Independence Award, April 2021
- NIH Center for Scientific Review,
ZRG1 IDIB-N 02 M, Member Conflict: AIDS Related Research
Ad-hoc member (R01, R01, R21, R03, K01, K23, K99 parent announcements; NIAID)
July 2021
- UNC Center for AIDS Research Developmental Core
Reviewer, CFAR Developmental Research Grant Program
September 2021
- Michigan Diabetes Research Center (MDRC) Diabetes Interdisciplinary Study Program
Reviewer
October 2021
- 2020 NIH Center for Scientific Review,
2021/01 HIV Comorbidities and Clinical Studies Study Section
Division of Physiological and Pathological Sciences, Immunology Integrated Review Group
Ad-hoc member (R01, R01, R21, R03, K01, K23, K99 parent announcements; NIAID)
- NIH Center for Scientific Review,
ZRG1 AARR-J (41) P, Special Emphasis Panel for Review of PAR-19-345, NIDA
Program Project Grant Applications (P01; NIDA)
- 2019 NIH Center for Scientific Review,
ZRG1 AARR-J (51) R, Special Emphasis Panel for Review of RFA AI-18-057, Long-acting Drug Delivery Systems for ART Optimization in HIV-1 Infected Children (R61/R33; NIAID)
- 2019 NIH Center for Scientific Review,
ZRG1 BDCN-S (02), Member Conflicts: International and Cooperative Projects (K43/D43; Fogarty Center)
- 2017 Emory University Center for AIDS Research K Supplement Developmental Award
- 2015 National Institute of Allergy and Infectious Diseases, NIH
PA-14-049: Mentored Career Development Award (K23)
- 2014 Eunice Kennedy Shriver National Institute of Child Health & Human Development, National Institutes of Health
RFA-13-008/009: Prevention of HIV transmission and acquisition through a better understanding of reproductive health.

2014 National Institute of Allergy and Infectious Diseases, NIH
RFA-12-018: Clinical Trial Units for NIAID Networks (UM1)

State and National Committees and Service

2022--2023 American College of Clinical Pharmacy Medication Expert Guidelines: Pharmacotherapy
of Heavily Treatment-Experienced People with HIV using Novel Agents
Writer, Lenacapavir Recommendations

2019-present MACS/WIHS Clinical Cohort Study Pharmacology Working Group
Co-Chair, 2019-present

Society of Infectious Disease Pharmacists
Research Award Committee

2017-2020 Society of Infectious Diseases Pharmacists
Elections Committee

2016-2019 Women's Interagency HIV Study Pharmacology Working Group
Chair, 2017-2019

2014-2020 International Society for Pharmacometrics
Regional RTP-ISoP Meeting Organizing Committee

March 2018 Co-Chair and Session Moderator, *Inaugural Pharmacometrics Skills Competition:
Model-Based Drug Development Grand Prix*
American Society of Clinical Pharmacology and Therapeutics Annual Meeting
Orlando, FL

2015-2016 Society of Infectious Diseases Pharmacists
Elections Committee
Annual Report Committee

Service to the University of North Carolina

2024—present Director of Graduate Studies, Division of Pharmacotherapy and Experimental Therapeutics
Member, Graduate Education Committee
Poster Reviewer, 2024 and 2025 Pharmaceutical Sciences Research Retreat
Breakout Discussion Group Leader, 2025 Pharmaceutical Sciences Research Retreat
Pharmaceutical Sciences Graduate Program Self Study Division Leader
UNC Eshelman School of Pharmacy

2021—present Member, UNC Center for AIDS Research Internal Advisory Board
Biostatistics Core
Developmental Core
Clinical Core

July 2021 Speaker, UNC Eshelman School of Pharmacy Innovation and Transformation in
Pharmaceutical Science Virtual Meeting

April 2021	UNC WinS (Women in Science) 2021 Symposium Poster Session Poster Judge
2019- 2022	Director of Graduate Admissions, Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy Member, Graduate Education Committee
2018-2020	UNC Eshelman School of Pharmacy ACPE Self-Study Faculty and Staff Standards Sub- Committee Reviewer
2017-2024	Research and Scholarship in Pharmacy (RASP), Division of Pharmacotherapy and Experimental Therapeutics Co-Director, member of RASP Oversight Committee
2017-2020	Scholastic Achievement and Progressions Committee, UNC Eshelman School of Pharmacy
2009-present	Admissions Interviewer, UNC Eshelman School of Pharmacy
2017-2019	University Representative, UNC University Childcare Center/Victory Village Day Care Board of Directors <i>2018-2019: Board Secretary</i>
2017	Search Committees for A. Forrest-sponsored Research/Clinical Track Assistant Professor Positions (two)
2014-2018	Pharmacy Honors Committee, UNC Eshelman School of Pharmacy
2016	Member, Search Committee for Pharmacometrics Staff Scientist, UNC Eshelman School of Pharmacy
2015	Member, Search Committee for Tenure-Track Junior Pharmacometrician, UNC Eshelman School of Pharmacy
2014-2015	Member, Search Committee for Senior Pharmacometrician, UNC Eshelman School of Pharmacy
2009-2011	ACPE Self-Study Faculty and Staff Standards Sub-committee